Farallon Capital Management significantly increased its investment in pharmaceutical company Novo Nordisk, boosting its holdings by nearly 235% to 2.62 million shares. According to a quarterly disclosure, the reported value of the position grew from $28.74 million to $125.55 million. This regulatory filing, made public on August 14, 2026, reflects the firm's holdings as of June 30, 2026, and is not indicative of current-day trading activity.
The transaction increased Novo Nordisk's weight in Farallon's reported portfolio from 0.16% to 0.58%. The increased investment came during a period of high demand for Novo Nordisk's key GLP-1 drugs used in diabetes and weight-loss treatments. [6, 8] Farallon, a multi-strategy investment firm known for fundamental analysis, has not publicly stated its reasoning for the trade. [1, 2]